VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
The device delivers clear, high-quality images to support accurate diagnoses across a broad range of patient groups
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis
Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible
Bayer remains a key partner in Ginkgo Bioworks’ growing agricultural biologicals platform
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
Kygevvi combines two pyrimidine nucleosides, doxecitine and doxribtimine, which act by integrating deoxycytidine and deoxythymidine into skeletal muscle mitochondrial DNA
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Subscribe To Our Newsletter & Stay Updated
